Literature DB >> 12739326

Inflammatory bowel disease.

Kandice L Knigge1.   

Abstract

Inflammatory bowel disease (IBD) comprises a group of idiopathic diseases of the intestine characterized by chronic inflammation of the bowel with periods of exacerbation and remission. The 2 major categories of IBD are ulcerative colitis and Crohn's disease, and each disease is distinct both clinically and histologically. The exact cause of IBD remains unknown, but several theories have been proposed. Primary care physicians are frequently confronted with the initial diagnosis and management of patients with IBD, and medical treatment options have rapidly expanded in recent years. This article reviews the epidemiology and pathogenesis of IBD; its clinical presentations and complications, which are essential to understanding this complex disease; and the available treatment options.

Entities:  

Mesh:

Year:  2002        PMID: 12739326     DOI: 10.1016/s1098-3597(02)90005-0

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  9 in total

1.  Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene.

Authors:  Katharine H Banner; Christophe Cattaneo; Jean-Loic Le Net; Aleksandar Popovic; David Collins; Jeremy D Gale
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

2.  Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease.

Authors:  Matilde De Simone; Michele M Ciulla; Ugo Cioffi; Luca Poggi; Barbara Oreggia; Roberta Paliotti; Fiorenzo Botti; Alberto Carrara; Fiorenza Agosti; Alessandro Sartorio; Ettore Contessini-Avesani
Journal:  J Gastrointest Surg       Date:  2007-08-09       Impact factor: 3.452

3.  Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.

Authors:  Virginia L Priest; Evan J Begg; Sharon J Gardiner; Christopher M A Frampton; Richard B Gearry; Murray L Barclay; David W J Clark; Paul Hansen
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis.

Authors:  Joshua-Ka-Shun Ko; Flora-Ying-Lee Lam; Andrew-Pok-Lap Cheung
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

5.  Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats.

Authors:  Jaleh Varshosaz; Jaber Emami; Afshin Fassihi; Naser Tavakoli; Mohsen Minaiyan; Fatemeh Ahmadi; Parvin Mahzouni; Farid Dorkoosh
Journal:  Int J Colorectal Dis       Date:  2010-07-29       Impact factor: 2.571

6.  Synthesis of a novel PEGylated colon-specific azo-based 4- aminosalicylic acid prodrug.

Authors:  Fatemeh Sadeghi; Atie Eidizade; Farinaz Saremnejad; Farzin Hadizadeh; Elham Khodaverdi; Abbas Akhgari
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

7.  The role of zinc and metallothionein in the dextran sulfate sodium-induced colitis mouse model.

Authors:  C D Tran; J M Ball; S Sundar; P Coyle; G S Howarth
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

8.  Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in rat.

Authors:  Jaleh Varshosaz; Fatemeh Ahmadi; Jaber Emami; Naser Tavakoli; Mohsen Minaiyan; Parvin Mahzouni; Farid Dorkoosh
Journal:  Int J Prev Med       Date:  2010

9.  Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice.

Authors:  Baoren Zhang; Yi Liu; Xu Lan; Xiaoxi Xu; Xiaoning Zhang; Xiang Li; Yiming Zhao; Guang Li; Caigan Du; Shanzheng Lu; Hao Wang
Journal:  J Transl Med       Date:  2018-03-20       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.